Strategic Collaboration Between Adaptimmune and Genentech to Research, Develop, and Commercialize Cancer-targeted Allogeneic T-cell Therapies Terminated
Strategic Collaboration Between Adaptimmune and Genentech to Research, Develop, and Commercialize Cancer-targeted Allogeneic T-cell Therapies Terminated
Company remains focused on launching afami-cel later this year with a PDUFA date of August 4th and developing its broader sarcoma franchise
公司仍然專注於在今年晚些時候推出afami-cel，PDUFA的日期爲8月4日第四 並發展其更廣泛的肉瘤系列
Update on afami-cel launch plans to be provided at the April 18th Investor Day
afami-cel 發射計劃的最新情況將在4月18日公佈第四 投資者日
Philadelphia, Pennsylvania and Oxford, United Kindgom--(Newsfile Corp. - April 12, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining the treatment of solid tumor cancers with cell therapy, today announced that its strategic collaboration with Genentech entered in 2021, has been terminated.
賓夕法尼亞州費城和英國牛津--（Newsfile Corp.，2024年4月12日）——重新定義細胞療法治療實體瘤癌的公司Adaptimmune Therapeutics plc（納斯達克股票代碼：ADAP）今天宣佈，與基因泰克於2021年開始的戰略合作已經終止。
Adrian Rawcliffe, Adaptimmune's Chief Executive Officer: "We've had a very valuable collaboration with our partner Genentech, and we continue to believe in the long-term potential of our iPSC-based allogeneic platform. Over the past 12 months, we've been resolutely focused on our late-stage autologous pipeline - in particular, our sarcoma franchise. We have the resources to deliver afami-cel to market as planned, and I look forward to updating on progress at our Investor Day next week."
Adaptimmune 首席執行官阿德里安·羅克利夫： “我們與合作伙伴基因泰克進行了非常寶貴的合作，我們仍然相信基於iPsc的異體平台的長期潛力。在過去的12個月中，我們一直堅定地專注於後期的自體產品線，尤其是我們的肉瘤特許經營權。我們有足夠的資源按計劃將afami-cel推向市場，我期待在下週的投資者日上公佈最新進展情況。”
About Adaptimmune
Adaptimmune is a cell therapy company working to redefine how cancer is treated. With personalized medicines that radically improve the patient's experience with the therapy as much as the therapy itself, Adaptimmune is tackling difficult-to-treat solid tumor cancers so that patients and families may experience more unforgettable and important personal moments. The Company's unique engineered T-cell receptor (TCR) platform enables the engineering of T-cells to target and destroy cancers across multiple solid tumor types.
關於 Adaptimmune
Adaptimmune是一家細胞療法公司，致力於重新定義癌症的治療方式。Adaptimmune的個性化藥物可以從根本上改善患者的治療體驗和療法本身，從而應對難以治療的實體瘤癌，從而使患者和家屬能夠體驗更難忘和重要的個人時刻。該公司獨特的工程化T細胞受體（TCR）平台使T細胞的工程設計能夠靶向和摧毀多種實體瘤類型的癌症。
Forward-Looking Statements
This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA). These forward-looking statements involve certain risks and uncertainties. Such risks and uncertainties could cause our actual results to differ materially from those indicated by such forward-looking statements, and include, without limitation: the success, cost and timing of our product development activities and clinical trials and our ability to successfully advance our TCR therapeutic candidates through the regulatory and commercialization processes. For a further description of the risks and uncertainties that could cause our actual results to differ materially from those expressed in these forward-looking statements, as well as risks relating to our business in general, we refer you to our Annual Report on Form 10-K filed with the Securities and Exchange Commission for the year ended 31 December, 2023, our Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and other filings with the Securities and Exchange Commission. The forward-looking statements contained in this press release speak only as of the date the statements were made and we do not undertake any obligation to update such forward-looking statements to reflect subsequent events or circumstances.
前瞻性陳述
本新聞稿包含1995年《私人證券訴訟改革法》（PSLRA）所指的 “前瞻性陳述”。這些前瞻性陳述涉及某些風險和不確定性。此類風險和不確定性可能導致我們的實際結果與此類前瞻性陳述所示結果存在重大差異，包括但不限於：我們的產品開發活動和臨床試驗的成功、成本和時機，以及我們通過監管和商業化程序成功推進TCR候選療法的能力。要進一步描述可能導致我們的實際業績與這些前瞻性陳述中表達的業績存在重大差異的風險和不確定性以及與我們的總體業務相關的風險，請參閱我們向美國證券交易委員會提交的截至2023年12月31日止年度的10-K表年度報告、10-Q表季度報告、8-K表最新報告以及向美國證券交易委員會提交的其他文件。本新聞稿中包含的前瞻性陳述僅代表截至聲明發表之日，我們沒有義務更新此類前瞻性陳述以反映隨後的事件或情況。
Adaptimmune Contact
適應免疫接點
Investor Relations
Juli P. Miller, Ph.D. - VP, Corporate Affairs and Investor Relations
M : +1 215 460 8920
Juli.Miller@adaptimmune.com
投資者關係
Juli P. Miller，博士-公司事務和投資者關係副總裁
M: +1 215 460 8920
Juli.Miller@adaptimmune.com
Media Relations
Dana Lynch, Senior Director of Corporate Communications
M: +1 267 990 1217
Dana.Lynch@adaptimmune.com
媒體關係
達娜·林奇，企業傳播高級董事
M: +1 267 990 1217
Dana.Lynch@adaptimmune.com
譯文內容由第三人軟體翻譯。